HCM Archives - Page 3 of 6

2 minute read

Takeda And HUTCHMED Announce New Drug Application For Fruquintinib For Treatment Of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

May 25, 4:32 PM

− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023 − NDA Includes Results From the Phase 3 FRESCO-2 and FRESCO Clinical Trials Takeda ((TAK) and HUTCHMED (China)

HCM

3 minute read

Reported Late Monday April 17, HUTCHMED Announces NDA Acceptance In China For Fruquintinib In Second-Line Gastric Cancer

By Happy Mohamed

April 18, 12:31 AM

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that its New Drug Application ("NDA") for fruquintinib in combination with paclitaxel for the treatment of second-line

HCM

2 minute read

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday

By Lisa Levin

April 13, 10:38 AM

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

ALLO

4 minute read

Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

April 6, 1:24 PM

Gainers Liquid Media Group Ltd. (NASDAQ: YVR) jumped 88.1% to $0.2719.

$APE

2 minute read

Lamb Weston, TH International, AMC Entertainment And Other Big Stocks Moving Higher On Thursday

By Lisa Levin

April 6, 10:25 AM

U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.

ADV

4 minute read

Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

April 4, 1:03 PM

Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43.

$APE

1 minute read

Movers

Why Is HUTCHMED Stock Trading Higher Today?

By Ye Kuang

April 4, 11:35 AM

HUTCHMED (China) Limited (NASDAQ: HCM) shares are trading higher on Tuesday after the company initiated enrollment registration for its ongoing Phase 2 trial of HMPL-453 for intrahepatic cholangiocarcinoma patients with fibroblast growth factor receptors 2 fusion.

HCM

1 minute read

News

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

By Benzinga Newsdesk

April 4, 5:35 AM

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National Medical Products Administration ("NMPA") and reached an agreement to initiate

HCM

5 minute read

Reported Late Thursday March 30, HUTCHMED Completes Rolling Submission Of NDA To U.S. FDA For Fruquintinib For The Treatment Of Refractory Metastatic Colorectal Cancer

By Happy Mohamed

March 31, 12:21 AM

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in

HCM

4 minute read

Why Miromatrix Medical Shares Are Trading Lower By 40%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

March 8, 2:28 PM

Gainers Kimball International, Inc. (NASDAQ: KBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million.

AMBI

Feed Symbols: HCM